Publication Date:
2013-05-25
Description:
Cramer et al. (Reports, 23 March 2012, p. 1503; published online 9 February 2012) reported that bexarotene rapidly reduces beta-amyloid (Abeta) levels and plaque burden in two mouse models of Abeta deposition in Alzheimer's disease (AD). We now report that, although bexarotene reduces soluble Abeta40 levels in one of the mouse models, the drug has no impact on plaque burden in three strains that exhibit Abeta amyloidosis.〈br /〉〈span class="detail_caption"〉Notes: 〈/span〉Veeraraghavalu, Karthikeyan -- Zhang, Can -- Miller, Sean -- Hefendehl, Jasmin K -- Rajapaksha, Tharinda W -- Ulrich, Jason -- Jucker, Mathias -- Holtzman, David M -- Tanzi, Rudolph E -- Vassar, Robert -- Sisodia, Sangram S -- New York, N.Y. -- Science. 2013 May 24;340(6135):924-f. doi: 10.1126/science.1235505.〈br /〉〈span class="detail_caption"〉Author address: 〈/span〉Department of Neurobiology, University of Chicago, Chicago, IL 60637, USA.〈br /〉〈span class="detail_caption"〉Record origin:〈/span〉 〈a href="http://www.ncbi.nlm.nih.gov/pubmed/23704555" target="_blank"〉PubMed〈/a〉
Keywords:
Alzheimer Disease/*drug therapy/*metabolism
;
Amyloid beta-Peptides/*metabolism
;
Animals
;
Apolipoproteins E/*metabolism
;
Brain/*metabolism
;
Male
;
Tetrahydronaphthalenes/*pharmacology/*therapeutic use
Print ISSN:
0036-8075
Electronic ISSN:
1095-9203
Topics:
Biology
,
Chemistry and Pharmacology
,
Computer Science
,
Medicine
,
Natural Sciences in General
,
Physics